(ATDN) New Type of HIV Drug

(ATDN) New Type of HIV Drug

Treatment Review No. 20; November 1995

To block HIV's infection of new cells, a class of drugs called NNRTIs (non-nucleoside reverse transcriptase inhibitors) is being developed. NNRTIs stop the reverse transcriptase which is the part of HIV required to make new virus and infect more cells. However, HIV has quickly developed resistance to the effects of the NNRTIs that are currently being studied. A new anti-HIV drug in this class, called HBY 097, is being studied at New York University Medical Center. Laboratory studies of HBY 097 suggest that HIV may weaken itself when it becomes resistant to HBY 097. This weakened HIV may not be as harmful to the body as normal HIV. The new study will last 12 weeks. To be eligible participants cannot have taken any anti-HIV drugs, and have T cell counts between 200 and 500. Study participants will be divided into three groups. One group will receive their assigned dose of HBY 097 alone. A second group will take their assigned dose of HBY 097 and AZT. A third group will take AZT alone. Neither the doctor nor the person taking part in the study will know which treatment is being taken. If you are interested in taking part in this study, call the Network at (800) 734-7104, or in New York City you can call (800) 448-2775.

951101
ATR02004

Always watch for outdated information. This article first appeard in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1995 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1995. AEGIS.